Publications by authors named "Fabian Locquet"
Article Synopsis
- Three types of small RNA therapeutics—siRNAs, miRNAs, and ASOs—have advantages over traditional drugs by targeting gene products, offering new treatment avenues for various diseases.
- While these small RNAs are valuable in preclinical research for gene silencing and drug target validation, off-target effects, particularly miRNA-like ones, can complicate results and lead to adverse effects.
- The review discusses strategies such as sequence design and AI-based predictions to minimize these off-target effects, providing a comprehensive overview of current computational methods and experimental validation techniques to support small RNA therapy development.
Article Synopsis
- Cardiac hypertrophy, triggered by sympathetic nervous system activation, can lead to heart failure, and the transcription factor YB-1 may play a key role in managing this process.
- In human heart biopsies from patients with ischemic cardiomyopathy, YB-1 expression is found to be downregulated, which correlates with the development of heart failure.
- Research using siRNA techniques on cardiac cells indicates that reducing YB-1 leads to increased hypertrophic growth, while overexpressing YB-1 can inhibit hypertrophic responses under certain stimuli, suggesting that maintaining YB-1 levels is crucial for heart protection.
Matrix Metalloproteinases Repress Hypertrophic Growth in Cardiac Myocytes.
Cardiovasc Drugs Ther
April 2021
Purpose: Matrix metalloproteinases (MMPs) are identified as modulators of the extracellular matrix in heart failure progression. However, evidence for intracellular effects of MMPs is emerging. Pro- and anti-hypertrophic cardiac effects are described.
View Article and Find Full Text PDF